Ligand Pharm (LGND)
$88.02 1.48 (1.71%)
16:11 EST LGND Stock Quote Delayed 15 Minutes
Previous Close $88.02
Market Cap 1.87B
PE Ratio 41.13
Volume (Avg. Vol.) 276,800
Day's Range 85.94 - 88.60
52-Week Range 84.45 - 130.50
Dividend & Yield N/A (N/A)
LGND Stock Predictions, Articles, and Ligand Pharm News
- From InvestorPlace
- From the Web
The long-term outlook is rosy for these five biotech stocks. They have the pipelines, partners and marketed drugs to provide years of growth for investors.
These ten stocks aren't exactly household names, but they each deserve a spot in a list of small-cap stocks to buy now for traders that can deal with the risk for the potential of high reward.
After the market's rout, biotech stocks offer a huge value right now. Here are 5 that offer the best opportunities for investors.
On a year-to-date basis, SBIO still looks good, up 14.30%, or 310 basis points better than the Nasdaq Biotechnology Index. Year-to-date, SBIO is also outpacing the equal-weight S&P Biotechnology Select Industry Index.
These are the 10 best stocks to buy now. Regardless of market conditions, they should continue to climb for years to come.
We take a look at three biotech stocks whose share price has increased in the past month due to as the biotech industry bounced back in the past month after dec....
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio. Compare Brokers....
Even if volatility continues to rear its ugly head, these stocks have the earnings and sales growth to last a long time.
The biotech industry has posted a turnaround in the first half of the year, despite facing pricing issues in 2016.
This week, the ratings of 24 Biotechnology stocks on Portfolio Grader are down. Each of these rates a "D" ("sell") or "F" overall ("strong sell").
The Manufacturing sector saw plenty of trading activity today, including the following leaders and losers.
The grades of 4 Biotechnology stocks are better this week, according to the Portfolio Grader database. Every one of these stocks has an "A" ("strong buy") or "B" overall ("buy") rating.
The following stocks were moving the Manufacturing sector today.
Biotech stocks are never a sure thing, but these seven companies do pack a payload of promise. Look toward large pipelines and pathways to profits.
From Analyst Ratings
H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Ligand Pharma (LGND – Research Report) today and set a price target of $214.00. The company’s shares closed last Monday at $91.24, close to its 52-week low of $84.45. According to TipRanks.com, Pantginis is a 4-star analyst with an average return of 7.7% and a
From Market News Video
Investors in Ligand Pharmaceuticals Inc (LGND) saw new options become available this week, for the August 21st expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 220 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
From Seeking Alpha
From Talk Markets
Navellier RatingsPowered by Portfolio Grader